# US 2019/0315871 A1 · Methods of treating inflammatory and autoimmune diseases with natalizumab

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315871 A1
- Document ID: US20190315871A1
- Status: Published application
- Kind: A1
- Application number: 16/357,179
- Filed: 2019-03-18
- Published: 2019-10-17
- Earliest claimed: 2006-02-28
- Assignees: Biogen MA Inc.
- Applicants: Biogen Ma Inc.
- Inventors: Ivan Lieberburg
- Web page: https://patentgrep.com/patent/US20190315871A1

## CPC

- C07K 16/2839: {against the integrin superfamily}
- A61K 38/03: Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- A61K 38/215: {IFN-beta}
- A61K 39/39541: {against normal tissues, cells}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 49/0004: {Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/2842: {against integrin beta1-subunit-containing molecules, e.g. CD29, CD49}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- G01N 2333/025: Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
- G01N 2800/285: Demyelinating diseases; Multipel sclerosis
- G01N 2800/7095: Inflammation
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.

## Claims

### Claim 1

A method of using natalizumab to treat a patient with an inflammatory or autoimmune disease comprising:
(a) administering a pharmaceutically effective amount of natalizumab to the patient;
(b) monitoring the patient for indicators of progressive multifocal leukoencephalopathy (PML), wherein the monitoring comprises serially removing samples of the patient's blood, measuring the amount of IgG anti-JCV antibodies in the samples, and comparing the amount of the anti-JCV antibodies in the samples; and
(c) discontinuing the administration of natalizumab in the presence of indicators of progressive multifocal leukoencephalopathy (PML);
wherein the monitoring improves the safety of the treatment.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disease is multiple sclerosis.

### Claim 3 (depends on 2)

The method of claim 2, wherein the multiple sclerosis is selected from relapsing remitting, secondary progressive, primary progressive, and chronic progressive multiple sclerosis.

### Claim 4 (depends on 3)

The method of claim 3, wherein the disease is relapsing remitting multiple sclerosis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the disease is inflammatory bowel disease.

### Claim 6 (depends on 5)

The method of claim 5, wherein the disease is Crohn's disease.

### Claim at position 7

-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the monitoring further comprises testing for clinical and/or radiologic symptoms of progressive multifocal leukoencephalopathy (PML).

### Claim 11 (depends on 10)

The method of claim 10, wherein the testing for clinical symptoms comprises testing for new or worsening neurological symptoms.

### Claim 12 (depends on 11)

The method of claim 11, wherein the neurological symptoms comprise one or more of central blindness, mental confusion, personality change, and dyskinesia.

### Claim 13 (depends on 10)

The method of claim 10, wherein the testing for radiologic symptoms comprises performing a Gd-enhanced magnetic resonance imaging (MRI) scan.

### Claim at position 12

-76. (canceled)

### Claim 77 (depends on 1)

The method of claim 1, wherein the pharmaceutically effective amount is from 1 to 5 mg antibody per kilogram of body weight.

### Claim 78 (depends on 1)

the method of claim 1, wherein the pharmaceutically effective amount is 300 mg.

### Claim 79 (depends on 1)

The method of claim 1, wherein the natalizumab is administered repeatedly at intervals from two to eight weeks.

### Claim 80 (depends on 1)

The method of claim 1, wherein the monitoring the patient for indicators of PML further comprises detecting the presence of JCV in the patient's cerebrospinal fluid (CSF).

### Claim 81 (depends on 1)

The method of claim 1, wherein the monitoring the patient for indicators of PML further comprises:
(i) detecting seroconversion or an increasing titer of JCV by the comparing the amount of the antibodies in the samples;
(ii) removing a sample of the patient's cerebrospinal fluid after detecting the seroconversion or increasing titer of JCV; and
(iii) testing the cerebrospinal fluid for the presence of JCV.
